



Paris, July 19th 2022

SUBSTIPHARM acquires Efient® rights from Daiichi Sankyo in Europe, The United Kingdom, Switzerland and Turkey.

SUBSTIPHARM is very excited to announce that it has entered into an agreement to acquire the blood thinner drug Efient® from **Daiichi Sankyo** for an undisclosed amount.

EFFIENT® is indicated for the prevention of atherothrombotic events in patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI). It is currently marketed in most European countries, as well as the United Kingdom, Switzerland, and Turkey.

As a French based privately-owned company, **SUBSTIPHARM** is committed in keeping such mature products on the market, allowing patients to keep having access to their ongoing treatment.

Philippe Beaupere, Substipharm Head of Mergers & Acquisitions, commented:

“This acquisition is another step in our expansion strategy where we consolidate our existing business where Substipharm is already present while also embracing new partnerships in selected new territories. After the acquisition of Evista® a few years ago, we are delighted to work again with the Daiichi Sankyo teams and expect a very effective transition”.

The closing of the transaction is expected in late summer 2022.